Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07413809
PHASE3

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

Sponsor: The Affiliated People's Hospital of Ningbo University

View on ClinicalTrials.gov

Summary

This study employs a prospective, multicenter, randomized, two-arm design aimed at evaluating the efficacy and safety of the FTO regimen in preventing delayed chemotherapy-induced nausea and vomiting (CINV) following high-dose chemotherapy for hematopoietic stem cell transplantation (HSCT). A total of 92 patients with multiple myeloma who were indicated for autologous HSCT were enrolled. The primary endpoint was to compare the complete response (CR) rates of the FTO regimen versus the FTD regimen in the delayed phase (24-240 hours after chemotherapy) for preventing nausea and vomiting induced by high-dose chemotherapy during HSCT.

Official title: A Prospective, Multicenter, Randomized Controlled Trial of Fosaprepitant Combined With Tropisetron and Multi-Day Olanzapine Versus Fosaprepitant Combined With Tropisetron and Dexamethasone for the Prevention of Delayed Nausea and Vomiting Induced by High-Dose Chemotherapy in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

92

Start Date

2025-10-31

Completion Date

2027-09

Last Updated

2026-02-17

Healthy Volunteers

No

Interventions

DRUG

Fosaprepitant

150mg, intravenously every 72 hours from the initiation of preconditioning chemotherapy until day +6 after HSCT

DRUG

Fosaprepitant

150mg, intravenously 30 minutes before chemotherapy on day -3

DRUG

Tropisetron

5mg, intravenously 30 minutes before preconditioning chemotherapy on days -3 to -2

DRUG

Olanzapine

5mg, orally once daily at bedtime until day +8 after HSCT, or until the occurrence of an adverse drug event requiring study termination or death, whichever occurs first

DRUG

Dexamethasone

6mg, orally 30 minutes before chemotherapy on day -3; 3.75mg, orally on days -2 to 0

Locations (1)

The Affiliated People's Hospital of Ningbo University

Ningbo, Zhejiang, China